Abstracts tagged "DMARDs"

Abstract Number: 1713 • 2013 ACR/ARHP Annual Meeting
Disparity In Biologic Therapy In Ethnic Minorities With Rheumatoid Arthritis: Can It All Be Due To Lack Of Access To Drug?
Gail S. Kerr¹, Ted R. Mikuls², Christopher J. Swearingen³, Chunqiao Luo⁴ and Yusuf Yazici⁵, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Ethnic disparities in the administration of DMARDs exist, but the impact of differing health care systems on access in ethnic minorities treated by rheumatologists,…
Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
A. Dikranian¹, K. Soma², R. Riese², D. Gruben² and T. V. Jones³, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
P.H.P. de Jong¹, J.M.W. Hazes², K.H. Han³, A.M. Huisman⁴, D. van Zeben⁵, P.A. van der Lubbe⁶, A.H. Gerards⁶, B. van Schaeybroeck⁷, P.B. de Sonnaville⁸, M.V. Krugten⁹, J.J. Luime² and A.E.A.M. Weel³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁵Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁷Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…
Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
S. B. Cohen¹, Roy Fleischmann¹, J. M. Kremer², A. Koenig³, K. Kwok⁴, L. Wang⁵, C. a. Mebus⁵, R. Riese⁵ and T. Robinson³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Albany Medical College and The Center for Rheumatology, Albany, NY, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
Abstract Number: 1458 • 2013 ACR/ARHP Annual Meeting
Rates Of Switching and Healthcare Costs Associated With Switching Biologic Disease-Modifying Antirheumatic Drugs In a Commercial Population: Evidence From Real-World Observational Studies
A Nadkarni, F Lobo and T Juday, Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Several biologic disease-modifying antirheumatic drugs (bDMARDs) are approved for the treatment of moderate-to-severe RA. Switching between bDMARD therapies is common in real-world settings, and…
Abstract Number: 437 • 2013 ACR/ARHP Annual Meeting
Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang¹, Lang Chen³, Huifeng Yun⁴, Michael H. Schiff⁵, David Mackey⁶ and Seth Ginsberg⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Division, University of Colorado, Denver, CO, ⁶Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Creaky Joints, New York, NY
Background/Purpose: Although methotrexate (MTX) is the cornerstone of RA treatment, use of oral and subcutaneous (SC) preparations in real-world settings is not well characterized. Methods:…
Abstract Number: 1418 • 2013 ACR/ARHP Annual Meeting
Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
J. M. Kremer¹, J. D. Greenberg², C. Turesson³, D. Gruben⁴, C. A. Mebus⁴, E. Bananis⁵ and T. Robinson⁶, ¹Albany Medical College and The Center for Rheumatology, Albany, NY, ²Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ³Lund University, Malmö, Sweden, ⁴Pfizer Inc, Groton, CT, ⁵Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Cigarette smoking is a known risk factor for developing rheumatoid arthritis (RA).1 Several recent observational studies suggest that cigarette smoking may be associated with…
Abstract Number: 361 • 2013 ACR/ARHP Annual Meeting
Risk Of Venous Thromboembolism and Use Of Disease-Modifying Antirheumatic Drugs For Rheumatoid Arthritis
Seoyoung C. Kim¹, Daniel H. Solomon^2,3, Jun Liu⁴, Jessica M. Franklin⁵, Robert J. Glynn⁶ and Sebastian Schneeweiss⁷, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recent research suggests that rheumatoid arthritis (RA), an autoimmune systemic inflammatory disease, increases the risk of venous thromboembolism (VTE) including pulmonary embolism and deep…
Abstract Number: 198 • 2013 ACR/ARHP Annual Meeting
Accuracy Of International Classification Of Diseases (Ninth Revision) Coding For Rheumatoid Arthritis In The Primary Care Setting
Sheena Ogando¹, Karolina M. Weiss¹ and Harry D. Fischer², ¹Department of Medicine, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY, ²Division of Rheumatology, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY
Background/Purpose: Current quality measures are diagnosis driven and focus on management. For rheumatoid arthritis (RA), the Physician Quality Reporting System requires that a disease modifying…
Abstract Number: 1355 • 2013 ACR/ARHP Annual Meeting
Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Methotrexate
Uwe Pichlmeier and Kay-Uwe Heuer, medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of RA, psoriasis, and psoriatic arthritis. Subcutaneously administered MTX is well absorbed and appears to overcome…
Abstract Number: 378 • 2013 ACR/ARHP Annual Meeting
HBV Reactivation and Consequent Hepatitis In Rheumatoid Arthritis Patients With Different HBV Carring State: A Clinical Observation Follow-Up
Lie Dai, An Qi Liang, Ying Qian Mo, Jian Da Ma, Le Feng Chen, Dong Hui Zheng and Lang Jing Zhu, Division of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: Approximate 7.2% Chinese were infected with hepatitis B virus (HBV), and the prevalence of concurrent HBV carriers in Chinese rheumatoid arthritis (RA) patients was…
Abstract Number: 173 • 2013 ACR/ARHP Annual Meeting
HLA-DRB1*08:02 Is Associated With Bucillamine-Induced Proteinuria In Japanese Rheumatoid Arthritis Patients: A Case-Control Study
Hiroshi Furukawa¹, Shomi Oka¹, Kota Shimada², Shoji Sugii², Atsushi Hashimoto³, Akiko Komiya¹, Naoshi Fukui¹, Taiichiro Miyashita⁴, Kiyoshi Migita⁴, Akiko Suda⁵, Shouhei Nagaoka⁶, Naoyuki Tsuchiya⁷ and Shigeto Tohma¹, ¹Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ³Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁴Clinical Research Center, Nagasaki Medical Center, National Hospital Organization, Omura, Japan, ⁵Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁶Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, ⁷Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Bucillamine (Buc) is one of the commonly used disease-modifying anti-rheumatic drugs (DMARDs) in Japan. Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated…
Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Jaime Pachon¹, Alan Kivitz², Kay-Uwe Heuer³ and Uwe Pichlmeier³, ¹Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…
Abstract Number: 349 • 2013 ACR/ARHP Annual Meeting
Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis
Agnes Szentpetery¹, Mark Kilbane², Myra P. O'Keane², Muhammad Haroon³, Phil Gallagher⁴, Susan van der Kamp⁵, Malachi McMenna⁶ and Oliver FitzGerald³, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Metabolism Laboratory, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵DXA Unit, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁶Department of Endocrinology & Metabolic Bone Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: There is a growing interest in bone and cartilage biomarkers that could be used predicting and assessing changes in structural damage in inflammatory arthritis.…
Abstract Number: 2683 • 2013 ACR/ARHP Annual Meeting
Application Of a Multi-Biomarker Disease Activity (Vectra^® DA) Score For Assessing Rheumatoid Arthritis Patients With Fibromyalgia Or Low C-Reactive Protein
Yvonne C. Lee¹, James Hackett², Claire Alexander³, Michelle A. Frits¹, Christine K. Iannaccone¹, Nancy A. Shadick⁴, Michael E. Weinblatt⁵, Oscar Segurado⁶ and Eric H. Sasso⁶, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Hackett & Associates, Inc., San Diego, CA, ³Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁶Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: Clinical assessment of rheumatoid arthritis (RA) may be challenging if patients have fibromyalgia (FM) or if C-reactive protein (CRP) is low (£1 mg/dL). A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].